Correction : Transaction in Own Shares

SHIRE PLC - Correction : Transaction in Own Shares

PR Newswire

London, January 31

Transaction in Own Shares - Correction

January 31, 2013 - This announcement replaces Shire's announcement releasedtoday under Number 30138-F359.

The highest and lowest price paid for those Ordinary Shares acquired throughthe purchase of ADRs was incorrectly stated. All other details remainunchanged. The full amended text is shown below.

January 31, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"),announces that in accordance with the authority granted by shareholders at theCompany's Annual General Meeting on April 24, 2012 it purchased 15,997 of itsordinary shares of 5 pence each ("Ordinary Shares") on January 30, 2013 throughboth direct purchases of Ordinary Shares and through the purchase of OrdinaryShares underlying ADRs. The highest and lowest price paid for the directlyacquired Ordinary Shares was 2120.00 pence per share and 2115.00 pence pershare respectively and for those Ordinary Shares acquired through the purchaseof ADRs was 3344.33 cents per share and 3335.67 cents per share respectively.

The purchased shares will be held as treasury shares. Following the abovepurchase, the Company holds 4,666,374 Ordinary Shares as treasury shares andhas 557,888,789 Ordinary Shares in issue (excluding treasury shares).

The purchases were made by an independent third party which makes its tradingdecisions independently of, and uninfluenced by the Company. The independenceof the third party enables the Company to continue to purchase Ordinary Shares(including Ordinary Shares underlying ADRs) during close periods and otherprohibited periods, should they arise. The third party has been appointed bythe Company to make purchases to December 31, 2013.

For further information please contact:

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and providehealthcare in the areas of:

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value forpatients, physicians, policymakers, payors and our shareholders.

www.shire.com